Status:

COMPLETED

Investigating Superion™ In Spinal Stenosis

Lead Sponsor:

Boston Scientific Corporation

Collaborating Sponsors:

VertiFlex, Incorporated

Conditions:

Lumbar Spinal Stenosis

Intermittent Claudication

Eligibility:

All Genders

45+ years

Phase:

NA

Brief Summary

The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffer...

Detailed Description

The proposed prospective, multi-center, randomized clinical trial is designed to evaluate the safety and effectiveness of the Superion™ ISS compared to the X-STOP® IPD® device in healthy adults suffer...

Eligibility Criteria

Inclusion

  • Male or female subjects ≥ 45 years of age
  • Persistent leg/buttock/groin pain, with or without back pain, that is relieved by flexion activities (example: sitting or bending over a shopping cart)
  • Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral recess), and the nerve root canal (foraminal)
  • Must be able to sit for 50 minutes without pain and to walk 50 feet or more

Exclusion

  • Axial back pain only
  • Fixed motor deficit
  • Diagnosis of lumbar spinal stenosis which requires any direct neural decompression or surgical intervention other than those required to implant the control or experimental device
  • Unremitting pain in any spinal position
  • Significant peripheral neuropathy or acute denervation secondary to radiculopathy
  • Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
  • Significant instability of the lumbar spine as defined by 3mm translation or 5 degrees angulation
  • Sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and/or hips
  • Spondylolisthesis or degenerative spondylolisthesis greater than grade 1.0 (on a scale of 1 to 4)
  • Spondylolysis (pars fracture)
  • Morbid obesity, defined as Body Mass Index (BMI) greater than 40kg/m2
  • Insulin-dependent diabetes mellitus
  • Prior surgery of the lumbar spine
  • Cauda equina syndrome (defined as neural compression causing neurogenic bowel or bladder dysfunction)
  • Infection in the disc or spine, past or present
  • Paget's disease at involved segment or metastasis to the vertebra, osteomalacia, or other metabolic bone disease
  • Tumor in the spine or a malignant tumor except for basal cell carcinoma
  • Involved in pending litigation of the spine or worker's compensation related to the back

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2017

Estimated Enrollment :

391 Patients enrolled

Trial Details

Trial ID

NCT00692276

Start Date

June 1 2008

End Date

February 1 2017

Last Update

November 16 2020

Active Locations (32)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 8 (32 locations)

1

Arizona Center for Neurosurgery

Phoenix, Arizona, United States, 85020

2

Tucson Orthopaedic Institute

Tucson, Arizona, United States, 85712

3

D.I.S.C. Sports and Spine Center

Beverly Hills, California, United States, 90211

4

Tower Orthopaedics and Sports Medicine/ Institute for Advanced Spinal Research

Beverly Hills, California, United States, 90211